• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Theranostics. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients

tetano

Editor, Senior Moderator
Theranostics. 2020 Apr 27;10(12):5613-5622. doi: 10.7150/thno.45985. eCollection 2020.
CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients.


Liu F[SUP]1[/SUP], Zhang Q[SUP]2,[/SUP][SUP]3,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], Huang C[SUP]2,[/SUP][SUP]5[/SUP], Shi C[SUP]6[/SUP], Wang L[SUP]1[/SUP], Shi N[SUP]1[/SUP], Fang C[SUP]2,[/SUP][SUP]5[/SUP], Shan F[SUP]1[/SUP], Mei X[SUP]7[/SUP], Shi J[SUP]2[/SUP], Song F[SUP]1[/SUP], Yang Z[SUP]2[/SUP], Ding Z[SUP]2[/SUP], Su X[SUP]5[/SUP], Lu H[SUP]8[/SUP], Zhu T[SUP]9[/SUP], Zhang Z[SUP]6[/SUP], Shi L[SUP]2,[/SUP][SUP]5[/SUP], Shi Y[SUP]1[/SUP].

Author information




Abstract

Rationale: Some patients with coronavirus disease 2019 (COVID-19) rapidly develop respiratory failure or even die, underscoring the need for early identification of patients at elevated risk of severe illness. This study aims to quantify pneumonia lesions by computed tomography (CT) in the early days to predict progression to severe illness in a cohort of COVID-19 patients. Methods: This retrospective cohort study included confirmed COVID-19 patients. Three quantitative CT features of pneumonia lesions were automatically calculated using artificial intelligence algorithms, representing the percentages of ground-glass opacity volume (PGV), semi-consolidation volume (PSV), and consolidation volume (PCV) in both lungs. CT features, acute physiology and chronic health evaluation II (APACHE-II) score, neutrophil-to-lymphocyte ratio (NLR), and d-dimer, on day 0 (hospital admission) and day 4, were collected to predict the occurrence of severe illness within a 28-day follow-up using both logistic regression and Cox proportional hazard models. Results: We included 134 patients, of whom 19 (14.2%) developed any severe illness. CT features on day 0 and day 4, as well as their changes from day 0 to day 4, showed predictive capability. Changes in CT features from day 0 to day 4 performed the best in the prediction (area under the receiver operating characteristic curve = 0.93, 95% confidence interval [CI] 0.87~0.99; C-index=0.88, 95% CI 0.81~0.95). The hazard ratios of PGV and PCV were 1.39 (95% CI 1.05~1.84, P=0.023) and 1.67 (95% CI 1.17~2.38, P=0.005), respectively. CT features, adjusted for age and gender, on day 4 and in terms of changes from day 0 to day 4 outperformed APACHE-II, NLR, and d-dimer. Conclusions: CT quantification of pneumonia lesions can early and non-invasively predict the progression to severe illness, providing a promising prognostic indicator for clinical management of COVID-19.
? The author(s).



KEYWORDS:

Artificial intelligence; COVID-19; Chest CT; Retrospective cohort; Severe illness


PMID:32373235PMCID:PMC7196293DOI:10.7150/thno.45985
[Indexed for MEDLINE]Free full text
 
Back
Top